9M 2023 Financial Overview

9M 2023: Business update Strong business performance in the first nine months of 2023 $ Robust revenue performance DKK 15bn Revenue Double-digit growth of strategic brands DKK 10bn 68% of total revenue ه 0000 Strong profit achievements Advancing R&D pipeline +9% (+10% reported) Revenue growth +81% (+79% reported) Vyepti revenue growth +16% (+14% reported) Strategic brands revenue growth Positive indicators persist in the launch of Rexulti AADAD DKK 5bn Adj. EBITDA +20% (+31% reported) Adj. EBITDA growth 32.5% Adj. EBITDA margin PACAP POC data presented at the IHC in Seoul HLR of the two PTSD phase III trials obtained in September 3 Unless otherwise stated, growth rates are at CER. AADAD: agitation associated with dementia due to Alzheimer's disease. PoC: proof of concept. IHC: International Headache Congress Lundbeck

View entire presentation